{
    "nctId": "NCT05045638",
    "briefTitle": "Effect of Coadministration of Sotorasib on the Pharmacokinetics of Rosuvastatin in Healthy Participants",
    "officialTitle": "A Phase I, Open-label, Fixed Sequence Crossover Study to Investigate the Effect of Coadministration of Sotorasib on the Pharmacokinetics of Rosuvastatin, a Breast Cancer Resistance Protein Substrate, in Healthy Subjects",
    "overallStatus": "COMPLETED",
    "conditions": "Healthy Participants",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "BASIC_SCIENCE",
    "enrollmentCount": 13,
    "primaryOutcomeMeasure": "Maximum Observed Plasma Concentration (Cmax) of Rosuvastatin",
    "eligibilityCriteria": "Inclusion criteria:\n\n* Healthy male subjects or female subjects, between 18 and 60 years of age (inclusive), at the time of Screening.\n* Body mass index, between 18 and 30 kg/m2 (inclusive), at the time of Screening.\n* Females of nonchildbearing potential\n\nExclusion criteria:\n\n* Inability to swallow oral medication or history of malabsorption syndrome.\n* History of hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator (or designee) and in consultation with the Sponsor.\n* Poor peripheral venous access.\n* History or evidence, at Screening or Check in, of clinically significant disorder, condition, or disease, including history of myolysis, not otherwise excluded that, in the opinion of the Investigator (or designee), would pose a risk to subject safety or interfere with the study evaluation, procedures, or completion.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT"
}